ESR1 and breast carcinoma: Tamoxifen was the first targeted therapy for breast cancer which was given to ER+ (estrogen receptor-positive) breast cancer patients to bind to estrogen receptor (ER) and antagonize the proliferative ability potentiated by binding of ER to growth hormone estrogen (10).